The C14 Foundation and consultancy group, established by CEO Martina Molsbergen, is a development story for Biotron IMO. C14 appears to be well-suited to identifying a partner for BIT225. Martina’s dedication to addressing the critical issue of rising mortality in endemic disease rates , especially in the developing world, meets her C14 foundation objectives. With a track record of operations since 2009, C14 has been involved in numerous successful projects. The team boasts impressive expertise in strategic partnerships. Why Lux would you be critical of a strategic corporate move?
BIT Price at posting:
1.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)